코오롱생명과학
Financials
Valuation Metrics
코오롱생명과학's Market Cap is ₩1674B. At end of 2025 it was ₩6768B. Ranked #910 of 2,410 in KR market (top 38%), #427 of 1,631 on KOSDAQ (top 26%), #107 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 46%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 167.43B KRW | KR#910/2,410 Sec#107/231 |
| Revenue | 211.44B KRW | KR#996/2,410 Sec#57/231 |
| Net Income | 34.63B KRW | KR#522/2,410 Sec#32/231 |
| Total Assets | 1.08T KRW | KR#460/2,410 Sec#26/231 |
| Net Assets | 696.93B KRW | KR#389/2,410 Sec#25/231 |
| Employees | 444 | KR#551/2,410 Sec#44/231 |
| Value | ||
| P/E | 4.84x | KR#376/2,410 Sec#13/231 |
| P/B | 0.24x | KR#237/2,410 Sec#9/231 |
| P/S | 0.79x | KR#1,282/2,410 Sec#69/231 |
| EV/EBITDA | 24.35x | KR#1,131/2,410 Sec#69/231 |
| FCF Yield | -16.76% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | 4.97% | KR#1,101/2,410 Sec#77/231 |
| ROA | 3.19% | KR#1,015/2,410 Sec#78/231 |
| Op. Margin | 8.69% | KR#607/2,410 Sec#50/231 |
| Revenue Growth | 17.09% | KR#619/2,410 Sec#58/231 |
| Financial Health | ||
| Debt Ratio | 55.55% | KR#1,040/2,410 Sec#120/231 |
| Total Debt | 310.61B KRW | KR#398/2,410 Sec#21/231 |
| FCF | -28.05B KRW | KR#1,966/2,410 Sec#189/231 |
| Cash | 30.70B KRW | KR#1,000/2,410 Sec#67/231 |
| Current Ratio | 0.76x | KR#1,974/2,410 Sec#193/231 |
| Net Debt/EBITDA | 15.24x | KR#1,328/2,410 Sec#94/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -61.01% | KR#2,169/2,410 Sec#203/231 |
| 1M Return | -11.43% | KR#1,361/2,410 Sec#137/231 |
| From 52W High | -82.41% | KR#2,336/2,410 Sec#218/231 |
| 1Y MDD | -82.51% | KR#2,320/2,410 Sec#213/231 |
| Trading | ||
| Volume | 17,508 shares | KR#1,004/2,410 Sec#101/231 |
| Trading Value | 220.6M KRW | KR#725/2,410 Sec#77/231 |
| Foreign Own. | 2.83% | KR#1,342/2,410 Sec#124/231 |
| Per Share | ||
| EPS | 2,645 KRW | KR#378/2,410 Sec#24/231 |
| BPS | 53,239 KRW | KR#251/2,410 Sec#15/231 |
Company Info
Kolon Life Science, established in 2000 and listed on KOSDAQ in 2009, focuses on the production of active pharmaceutical ingredients (APIs), antimicrobial agents, and bio-new drug research and development. Its pharmaceutical business supplies APIs and pharmaceutical intermediates globally, and it markets the eco-friendly antimicrobial brand Cleanbio for use in anti-dandruff shampoos and paints. The company is dedicated to cell and gene new drug development, concentrating on research and development for neuropathic pain treatments and anticancer drugs. Kolon Life Science is headquartered in Gangseo-gu, Seoul Metropolitan City.